Search PubMed⌕ Search

Biomedical subjects

K Janicki

Publications and source records attributed to K Janicki.

68 records · Page 4Linked to original sources
PubMedDate not supplied

[Correction of the symptoms of late substance withdrawal syndrome by intra-conjunctival administration of 5% homatropine solution (preliminary report)].

The "late" or post-acute alcohol withdrawal syndrome (PAWs) is characterized by recurring waves of psychosomatic disturbances, and return for alcohol for the relief of these symptoms is a commonplace in many of abstinent alcoholics. However, the exact mechanism(s) is not fully known and there is no established any rapid treatment. We now have some data which seem to confirm our original and successful experience with local homatropine in clearly defined cases of the PAW syndrome. 28 alcoholic inpatients suffering from severe signs of the post-acute alcohol withdrawal (PAW) syndrome were randomly administered either homatropine hydrobromide or placebo eyedrops. Administration of topical homatropine (two 0.5% drops were given twice being spaced 15 minutes apart), unlike that of placebo had, within 60 minutes, caused a significant and then usually maintained clinical improvement, as evidenced by decreases of intensity of the PAW symptoms (irritability, depressed mood, anxiety, somatic and vegetative disorders (p less than or equal to 0.01), as well as a considerable reduction of the self-rated "desire for drink" phenomenon (less than or equal to 0.01). Post-homatropine responses observed so far seem to be initiated by the reflexory-induced haemodynamic and thermoregulatory changes with a transient but still significant fall in the systolic blood pressure, pulse rate, and oral temperature. Of importance may be the fact that in majority of patients, the PAW symptoms decreased and well-being increased parallel with the fall in prolactin levels (p less than or equal to 0.01): this has usually been noted at 60 minutes after the first homatropine dosing and might indicate a possible involvement of, at least, the cholinergic-serotonergic pathways.(ABSTRACT TRUNCATED AT 250 WORDS)

Adult↗
PubMedDate not supplied

Influence of indobufen on occlusion of arteriovenous fistulas and some platelet activity in intermittent peritoneal dialysis patients.

Thrombotic complications constitute a significant problem connected with maintaining arteriovenous fistulas (A-V) for a long time. It has been established that platelets play an important role in the development of thrombosis in high flow systems. Aspirin and dipyridamole do not decrease the frequency of shunt thrombosis. Some of the more recently synthetised antiplatelet drugs (i.e. indobufen, 2-p-oxo-isoindolinyl-phenyl-butyric acid) could be promising in the prevention of such complications. The study group consisted of 40 patients in the terminal stage of renal failure treated with intermittent peritoneal dialysis (IPD). The A-V fistulas were formed by the same surgeon anesthetist team and this allowed for the elimination of technical errors. All patients were divided into two groups. Group I received indobufen at the dose of 2 x 100 mg/24 h orally. Group II received no antiplatelet treatment. The therapy started 24 h before A-V formation. The treatment was continued for 3 weeks. The following tests of platelet function were performed before indobufen therapy, after 9 h and 3 weeks of treatment: ADP and adrenaline induced platelet aggregation, platelet circulating aggregates, MDA level, platelet factor 3 and 4 and bleeding time. During indobufen treatment only a significant decrease in ADP induced aggregation was observed. No prolongation of the bleeding time was noted. No case of fistula thrombosis in indobufen group was observed. This complication, however, appeared in 3 patients (15%) of the control group (without antiplatelet therapy).

Adenosine Diphosphate↗